Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557369 | 1.00 | PRMT6 (0.48) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL29770525 | 0.93 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1096076 | 0.93 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23989259 | 0.90 | PRMT6 (0.45) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL28602756 | 0.90 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL28602758 | 0.90 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL3219117 | 0.90 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16648583 | 0.88 | PRMT6 (0.47) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL21333923 | 0.87 | PRMT6 (0.46) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL31039855 | 0.86 | PRMT6 (0.45) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178999-B1 | L-RIBO-LNA ANALOGUES | SANTARIS PHARMA AS (DK) | 2007-03-14 | — | — | EP | disclosed |
| US-7053207-B2 | L-ribo-LNA analogues | EXIQON A/S (DK) | 2006-05-30 | — | — | US | disclosed |
| US-20030087230-A1 | L-Ribo-LNA analogues | SANTARIS PHARMA A/S (DK) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087230-A1 | L-Ribo-LNA analogues | RNGTT, NCL, RNASEL | PRMT6 1065/4885PRKAB2 3036/4885PRKAG1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.